Revenue: As of FY2025 Q3, the actual value is USD 19.07 M, beating the estimate of USD 18.64 M.EPS: As of FY2025 Q3, the actual value is USD -0.11.EBIT: As of FY2025 Q3, the actual value is USD -2.951 M.<h3>Segment Revenue</h3><ul><li>Collaboration and License Revenue: $19.1 million for the three months ended September 30, 2025, compared to $2.3 million for the same period in 2024, and $30.1 million for the nine months ended September 30, 2025, compared to $4.6 million for the same period in 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: $16.3 million for the three months ended September 30, 2025, compared to $14.0 million for the same period in 2024, and $45.4 million for the nine months ended September 30, 2025, compared to $45.1 million for the same period in 2024.</li><li>Research and Development Expenses: $14.3 million for the three months ended September 30, 2025, compared to $10.8 million for the same period in 2024, and $37.9 million for the nine months ended September 30, 2025, compared to $32.4 million for the same period in 2024.</li><li>General and Administrative Expenses: $6.7 million for the three months ended September 30, 2025, compared to $6.3 million for the same period in 2024, and $22.3 million for the nine months ended September 30, 2025, compared to $18.3 million for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: $2.994 million for the nine months ended September 30, 2025, compared to $4.221 million for the same period in 2024.</li><li>Net Cash Used in Investing Activities: $423,000 for the nine months ended September 30, 2025, compared to $30,000 for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: $51.909 million for the nine months ended September 30, 2025, compared to $20.994 million for the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company anticipates that existing cash and cash equivalents, together with a $17.5 million development milestone received under its license agreement with Gilead, will be sufficient to fund operating expenses and capital expenditure requirements into the first quarter of 2027.</li><li>Non-Core Business: The company is actively seeking a partner to develop vilastobart in combination with PD-(L) 1 or PD1-VEGF in MSS mCRC and other tumor types.</li><li>Priority: The company expects to continue to incur significant expenses and operating losses for the foreseeable future, particularly to the extent it continues to advance its pipeline of novel, tumor-activated I-O molecules through preclinical and clinical development.</li></ul>

Xilio Therapeutics | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 19.07 M